ASH 2022 Conference Coverage
M

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
1,145 views
February 1, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Recommended

21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views

·

8 months ago
24:08

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

1.4K views

·

6 months ago
24:35

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

1.3K views

·

6 months ago
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views

·

9 months ago
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

700 views

·

4 months ago
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

726 views

·

6 months ago
14:32

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

434 views

·

3 months ago
27:47

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

648 views

·

6 months ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

881 views

·

7 months ago
22:21

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

266 views

·

3 months ago
24:27

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

540 views

·

5 months ago
23:35

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

670 views

·

6 months ago
08:18

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

898 views

·

10 months ago
37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

361 views

·

1 month ago
17:05

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

474 views

·

5 months ago
16:18

Masterclasses from the Wards

Masterclasses in Dermatology

S. Elman

317 views

·

8 months ago
04:16

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

394 views

·

5 months ago
18:04

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

932 views

·

1 year ago
27:37

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

2.7K views

·

1 year ago
AUTOPLAY